Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54
Jazyk angličtina Země Anglie, Velká Británie Médium print
Typ dokumentu časopisecké články, randomizované kontrolované studie, práce podpořená grantem
PubMed
31811715
DOI
10.1093/eurheartj/ehz821
PII: 5663567
Knihovny.cz E-zdroje
- Klíčová slova
- Antiplatelet drugs, Dual antiplatelet therapy, Medically managed, Myocardial infarction, Ticagrelor,
- MeSH
- adenosin terapeutické užití MeSH
- infarkt myokardu * farmakoterapie prevence a kontrola MeSH
- inhibitory agregace trombocytů škodlivé účinky MeSH
- kombinovaná farmakoterapie MeSH
- lidé MeSH
- purinergní receptory P2Y - antagonisté * terapeutické užití MeSH
- sekundární prevence MeSH
- ticagrelor terapeutické užití MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
- Názvy látek
- adenosin MeSH
- inhibitory agregace trombocytů MeSH
- purinergní receptory P2Y - antagonisté * MeSH
- ticagrelor MeSH
AIMS: PEGASUS-TIMI 54 demonstrated that long-term dual antiplatelet therapy (DAPT) with aspirin and ticagrelor reduced the risk of major adverse cardiovascular events (MACE), with an acceptable increase in bleeding, in patients with prior myocardial infarction (MI). While much of the discussion around prolonged DAPT has been focused on stented patients, patients with prior MI without prior coronary stenting comprise a clinically important subgroup. METHODS AND RESULTS: This was a pre-specified analysis from PEGASUS-TIMI 54, which randomized 21 162 patients with prior MI (1-3 years) and additional high-risk features to ticagrelor 60 mg, 90 mg, or placebo twice daily in addition to aspirin. A total of 4199 patients had no history of coronary stenting at baseline. The primary efficacy outcome (MACE) was the composite of cardiovascular death, MI, or stroke. Patients without history of coronary stenting had higher baseline risk of MACE [13.2% vs. 8.0%, adjusted hazard ratio (HR) 1.41, 95% confidence interval (CI) 1.15-1.73, in the placebo arm]. The relative risk reduction in MACE with ticagrelor (pooled doses) was similar in patients without (HR 0.82, 95% CI 0.68-0.99) and with prior stenting (HR 0.85, 95% CI 0.75-0.96; P for interaction = 0.76). CONCLUSION: Long-term ticagrelor reduces thrombotic events in patients with prior MI regardless of whether they had prior coronary stenting. These data highlight the benefits of DAPT in prevention of spontaneous atherothrombotic events and indicate that long-term ticagrelor may be considered in high-risk patients with prior MI even if they have not been treated with stenting. CLINICALTRIALS.GOV IDENTIFIER: NCT01225562.
Assistance Publique Hôpitaux de Paris 3 Avenue Victoria 75004 Paris France
AstraZeneca 431 53 Mölndal Sweden
Centre of Postgraduate Medical Education Grochowski Hospital Grenadierów 51 59 04 073 Warsaw Poland
Department of Cardiology Military Hospital Róbert Károly krt 1134 Budapest Hungary
Drammen Heart Center Dronninggata 28 3004 Drammen Norway
University Hospital Brno 20 Jihlavska Brno Czech Republic
University Hospital of Parma Via Gramsci 14 43126 Parma PR Italy
Citace poskytuje Crossref.org
Long-Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS-TIMI 54 Trial
ClinicalTrials.gov
NCT01225562